Sign In
Book a Demo

How AlphaLife uses AI automation to modernize the life sciences industry

The power of AI to process and analyze vast amounts of data at unprecedented speeds holds immense potential for revolutionizing scientific research. AI algorithms can identify patterns, correlations, and anomalies in complex datasets, leading to new discoveries and insights. AlphaPrime has positioned itself as a forerunner of this new frontier, developing SaaS products for the life sciences and healthcare industries. Their core product platform, AlphaPrime, offers a suite of products for protocol design and trials data collection using cloud computing, AI, and big data. AlphaPrime’s AI automation offerings are fully configurable to meet the needs of clinical trials and other health needs.

Jul 18, 2023 Read More

Connecting with OpenAI, AlphaLife Sciences Opens ChatGPT Function for Digitalization in Clinical Trials

May 9, 2023 — Singapore-based AlphaPrime Life Sciences (referred to as "AlphaPrime") announced the official integration of their clinical research cloud platform, AuroraPrime, with OpenAI's technology. This integration has enabled the practical application of ChatGPT in the digitalization and intelligence of clinical research. AlphaPrime has already begun exploring and expanding the application scenarios with several well-known innovative drug development companies. Additionally, AlphaPrime actively tests and fine-tunes the performance and effectiveness of various renowned AGI models in similar contexts, accelerating the exploration of large language models like ChatGPT in the field of clinical research.

May 09, 2023 Read More

AlphaLife: Using AI to turbocharge clinical trial processes

Sharon Chen is the CEO of AlphaPrime, a global health technology company. Prior to founding AlphaPrime, Sharon was the head of Verily China (Alphabet’s life science arm) and the Engineering Site Lead of Google Shanghai. Sharon is an IT veteran with 20+ years of rich experience in the industry, 15 of which were gained at Google. Sharon earned her bachelor’s degree in automation from Shanghai Jiaotong University, and her master’s degree in computer science from Texas A&M University.

Apr 14, 2023 Read More

AlphaLife Sciences Becomes RemeGen's Strategic Partner in Clinical Research Informationization

On April 6, 2023 — AlphaPrime Life Sciences Group (hereinafter referred to as "AlphaPrime"), announced in Shanghai that it has officially become a strategic partner for clinical research informationization with RemeGen Co., Ltd. (hereinafter referred to as "RemeGen"). As a leading domestic biopharmaceutical company, RemeGen will widely adopt the AuroraPrime clinical research platform from China to support the R&D pipeline of clinical trials, while AlphaPrime will fully support RemeGen's exploration and implementation of clinical research informationization to accelerate innovation.

Apr 06, 2023 Read More

AlphaLife Sciences Collaborates with CSPC to Explore Enterprise-level Intelligent Medical Writing System

On March 30, 2023 — AlphaPrime Life Sciences Group (hereinafter referred to as "AlphaPrime"), announced its collaboration with CSPC Pharmaceutical Group Co., Ltd (referred to as "CSPC"), one of China's leading innovative pharmaceutical companies, to officially launch the AuroraPrime Create (referred to as "Prime Create"), an intelligent clinical research document generation system. CSPC will fully utilize the system to write clinical research protocols and CSR (clinical study reports) to improve content writing, cross-team collaboration, and approval process efficiency, achieve digitization and structuring of document content, establish an enterprise-level content knowledge base, and realize comprehensive knowledge accumulation and application for innovative research and development.

Mar 30, 2023 Read More

AlphaLife CEO, Ms. Xiao Chen, Selected as One of Forbes China's Top 20 Promising Businesswomen in 2023

AlphaPrime Life Sciences, a company focused on the intelligent clinical research platform in the life sciences field, announced that its CEO, Ms. Xiao Chen (Sharon Chen), has been selected as one of Forbes China's Top 20 Promising Businesswomen for 2023. The list recognizes women who have made significant contributions to their respective industries and have demonstrated strong growth potential.AlphaPrime Life Science, a company focused on the intelligent clinical research platform in the life sciences field, announced that its CEO, Ms. Xiao Chen (Sharon Chen), has been selected as one of Forbes China's Top 20 Promising Businesswomen for 2023. The list recognizes women who have made significant contributions to their respective industries and have demonstrated strong growth potential.

Mar 10, 2023 Read More

AlphaLife Sciences Completes Tens of Millions of Dollars in A+ Round Financing, Empowering Digitalization of Life Science Clinical Research

October 12, 2022 — AlphaPrime Life Sciences, a new-generation leader in digitalizing life science clinical research, has recently completed tens of millions of dollars in A+ round financing. The round was led by Han Kang Capital with participation from B Capital, and exclusive financial advisory from Huaxing Capital.October 12, 2022 — AlphaPrime Life Sciences, a new-generation leader in digitalizing life science clinical research, has recently completed tens of millions of dollars in A+ round financing. The round was led by Han Kang Capital with participation from B Capital, and exclusive financial advisory from Huaxing Capital.

Oct 12, 2022 Read More

Product Launch: With Intelligent Content Recommendations, Prime Create 2.0 Clinical Research Document Generation System Is Online

On August 17, 2022 - AlphaPrime Life Sciences Group (hereinafter referred to as "AlphaPrime") confirmed that the independent and innovative clinical research document generation system, AuroraPrime Create (referred to as "Prime Create"), will undergo important updates with the release of version 2.0. As a unique professional writing system for the life science industry's information technology field, Prime Create 2.0 provides leading features such as intelligent content recommendations, a rich template library, and full-process collaborative management, ushering in a new era for clinical research document writing such as the trial protocol.

Aug 17, 2022 Read More

AlphaLife Sciences Completes RMB 100 Million A Round Financing

On July 22, 2021 - AlphaPrime Life Sciences, a leading provider of next-generation clinical research SaaS platforms, announced the completion of its RMB 100 million A round financing with participation from Lightspeed China, Hankang Capital, Lenovo Ventures, Primavera Venture, & etc..

Jul 22, 2021 Read More

Learn more about
AuroraPrime's leading solutions

Contact Us